26 May 2016 - CADTH is engaging with the pan-Canadian Pharmaceutical Alliance office (pCPA), and effective immediately will be including the pCPA office in the CADTH Common Drug Review  and pan-Canadian Oncology Drug Review processes.

This will provide an opportunity for the pCPA office to receive relevant information on drugs reviewed through the CDR and pCODR processes in a timely manner, as well as support business planning.

For more details, go to: https://www.cadth.ca/cdr-update-issue-119?utm_source=%2ALIVE%2A+CADTH%2FACMTS+Confirmed+Subscribers&utm_campaign=cc82c390bc-E_Alert_CDR_Update_119-5_26_2016&utm_medium=email&utm_term=0_2e3705996c-cc82c390bc-262951505